The research group discovered an effective method for the early detection of several types of cancer at the same time in whole blood and urine samples – the latest cancer research news review by BIOMEDICA CRO
In an international collaboration, researchers at Chalmers University of Technology, Sweden, have developed a new method for Multi-Cancer Early Detection (MCED) that is instead based on human metabolism. They showed that a new, previously untested method, can easily find multiple types of newly formed cancers simultaneously — including cancer types that are difficult to detect with comparable methods.
In a study totaling 1,260 participants, who donated whole blood and urine, the scientific group first discovered that the new method could detect all 14 cancer types that were tested.
The method is based on a discovery by Dr. Francesco Gatto and Prof. Jens Nielsen at Chalmers almost ten years ago: that so-called glycosaminoglycans — a type of sugar that is an important part of our metabolism — are excellent biomarkers to detect cancer noninvasively. The researchers developed a machine learning method in which algorithms are used to find cancer-indicating changes in glycosaminoglycans. The technique uses comparatively small blood or urine volumes, making them more practical and cheaper to use.
“To be able to find more cancer cases early, we know that new tools are needed. These results are very promising because of the demonstrated higher sensitivity across more types of cancer at stage I, using a cost-efficient and accessible technology,” says Dr. Eric Jonasch, MD, Professor at The University of Texas MD Anderson Cancer Center and co-author of the study.
Please find more information on the PNAS website, research articles, “Noninvasive detection of any-stage cancer using free glycosaminoglycans”.
Human biological samples collection by BIOMEDICA CRO: whole blood, urine, saliva, tissue samples, etc. for your research
BIOMEDICA CRO team is proud to participate in preclinical trials, in vitro diagnostics and developing new therapeutic approaches to human diseases since 2017. We are ready to provide all our knowledge and experience to support your current needs and collect high-quality human biospecimens and associated clinical data for your research.
Our primary area is oncology studies, such as:
• Breast cancer;
• Colorectal Cancer;
• Kidney Cancer;
• Cervical cancer;
• Testicular cancer;
• Lung cancer;
• Prostate Cancer, etc.
It is feasible to collect tissue samples (tumor/NAT FFPE blocks, fresh frozen tissue samples, histological slides, and lymph nodes), human blood samples (plasma, serum, buffy coat, PBMC) and other biofluids, such as stool, urine, etc. from cancer subjects.
In addition, we have contracted 50+ sites and departments with different disease areas.
BIOMEDICA CRO operates within the strictest ethical guidelines. It means that all clinical materials are exclusively obtained after approval of the Institutional Review Board or the Independent Ethical Committee (IRB/IEC) as well as all donors are mandatory consented and signed the Individual Consent Form.
Please email us to start our collaboration: office@biomedica-cro.com / LinkedIn.
